SURVIVAL AFTER ADJUVANT AND NEOADJUVANT CHEMOTHERAPY IN ELDERLY PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER: A CLEVELAND CLINIC EXPERIENCE

Suryanarayan Mohapatra, MD*1;Jyothirmai Seepana, MD2;Hamed Daw, MD3;Timothy Spiro, MD4;Jame Abraham, MD4;Paul Elson, ScD5 and Abdo Haddad, MD2, (1)Fairview Hospital, Cleveland Clinic Hospital, Cleveland, OH, (2)Fairview Hospital, Cleveland, OH, (3)Fairview Hospital,Cleveland Clinic Hospital, Cleveland, OH, (4)Cleveland Clinic, Cleveland, OH, (5)Cleveland Clinic Main Campus, Cleveland, OH

Meeting: Hospital Medicine 2017, May 1-4, 2017; Las Vegas, Nev.

Abstract number: 48

Categories: Geriatrics, Research Abstracts

Keywords: , ,

Background:

Triple negative breast cancer (TNBC) comprises of approximately 15% of the total breast cancers. There is limited data on treatment outcome of these patients in elderly population. We report our experience with elderly patients with TNBC treated at our tertiary care center.

Methods:

With IRB approval, the Cleveland Clinic’s database was used to identify TNBC patients treated between years 2000 to 2013. OS from the diagnosis of TNBC was the primary end point. Cox proportional hazard models with stepwise variable selections were used for data analysis.

Results:

A total of 223 patients, divided in to two groups, were retrospectively followed. The age group from 65-74 years consisted of “Group A” (N=140, median 69) and 75 or older formed “Group B” (N= 83, median 80, maximum 92). Eighty eight percent had ductal carcinoma. Clinically majority had stage I (50%) and stage II (33%) disease; 17% had stage III disease and most tumors were poorly differentiated (74%, grade 3). Slightly more than half the patients had lumpectomies (55%); and in only 13% of cases (25/190) were margins positive. Patients who received neoadjuvant (NACT), aduvant chemotherapy (ACT) and radiation therapy (RT) were 65%, 53% and 38% respectively. For NACT primarily doxorubicin, cyclophosphamide and paclitaxel were used whereas for ACT it was docetaxel with cyclophosphamide. Group B had somewhat poorer performance status than younger patients (p=.05), received chemotherapy especially neoadjuvant therapy much less frequently (p<.0001). OS and PFS were significantly lower in Group B (p=0.001 and 0.007 respectively). This holds true even if one adjusts for performance status and use of chemotherapy (p=0.04 and 0.03). Interestingly, the same trend is seen even if attention is restricted to just patients not treated with chemotherapy (p=0.004) or to just patients treated with adjuvant therapy (p=0.09 and 0.03, respectively).

Conclusions:

Among elderly patients with triple negative breast cancer, those above 75 years and older have poorer survival outcomes compared to those age 65-74 years.

This is a limited retrospective study and prospective studies are needed to further validate these findings.

To cite this abstract:

Mohapatra, S; Seepana, J; Daw, H; Spiro, T; Abraham, J; Elson, P; Haddad, A . SURVIVAL AFTER ADJUVANT AND NEOADJUVANT CHEMOTHERAPY IN ELDERLY PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER: A CLEVELAND CLINIC EXPERIENCE. Abstract published at Hospital Medicine 2017, May 1-4, 2017; Las Vegas, Nev. Abstract 48. https://www.shmabstracts.com/abstract/survival-after-adjuvant-and-neoadjuvant-chemotherapy-in-elderly-patients-with-triple-negative-breast-cancer-a-cleveland-clinic-experience/. Accessed December 14, 2018.

« Back to Hospital Medicine 2017, May 1-4, 2017; Las Vegas, Nev.